Consistent with our findings, CLARITY-IBD found that patients with IBD treated with infliximab had lower anti-S1 or neutralising antibodies against the SARS-CoV-2 wild-type and Omicron variants compared to those treated with vedolizumab after 2 or 3 vaccine doses.8 Here, PSMD1 is linked to inflammatory bowel disease.